FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2163863124> ?p ?o ?g. }

• W2163863124 endingPage "77" @default.
• W2163863124 startingPage "68" @default.
• W2163863124 abstract "ContextFatigue is highly prevalent in populations with advanced illness and is often associated with depressed mood. The role of psychostimulant therapy in the treatment of these conditions remains ill defined.ObjectivesTo evaluate the response of fatigue and depression in patients with advanced illness to titrated doses of methylphenidate (MP) as compared with placebo.MethodsIn a randomized, double-blind, placebo-controlled trial, 30 hospice patients, both inpatients and outpatients, who had fatigue scores of at least four on a scale of zero to 10 (0=no fatigue and 10=worst fatigue), were randomly assigned to receive either 5 mg of MP at 8 am and 1 pm or placebo. Doses of MP were titrated every three days according to response and adverse effects. Home care patients were monitored daily by telephone and visited by a research nurse on Study Days 0 (baseline), 3, 7, and 14. Fatigue was assessed using the Piper Fatigue Scale as the primary outcome measure and validated by the Visual Analogue Scale for Fatigue and the Edmonton Symptom Assessment Scale (ESAS) fatigue score. Subjects in inpatient facilities were interviewed or assessed by staff on an identical schedule. Depressive symptoms were assessed by the Beck Depression Inventory-II, Center for Epidemiologic Studies Depression Scale, and the ESAS depression score. Primary statistical analysis was conducted using repeated-measures multivariate analysis of the variance.ResultsBoth MP- and placebo-treated groups had similar measures of fatigue at baseline. Patients taking MP were found to have significantly lower fatigue scores (Piper Fatigue Scale, Visual Analogue Scale for Fatigue, and ESAS) at Day 14 compared with baseline. The improvement in fatigue with MP treatment was dose-dependent; the mean average effective dose was 10 mg on Day 3 and 20 mg on Day 14 (dose range of 10–40 mg). Placebo-treated individuals showed no significant improvement in fatigue. For patients with clinically significant depression on Day 0, treatment with MP was associated with a significant reduction in all test indices for depressed mood. For the placebo group, the changes in measures of depression were less than observed in the treatment group but were inconsistent between assessment tools. No significant toxicities were observed.ConclusionMP reduced symptoms of fatigue and depression when compared with placebo. The effect of MP on fatigue was dose-dependent and sustained over the duration of the study." @default.
• W2163863124 created "2016-06-24" @default.
• W2163863124 creator A5012914587 @default.
• W2163863124 creator A5044204093 @default.
• W2163863124 creator A5054494090 @default.
• W2163863124 creator A5061150813 @default.
• W2163863124 creator A5077121456 @default.
• W2163863124 creator A5080248259 @default.
• W2163863124 creator A5086475445 @default.
• W2163863124 date "2012-01-01" @default.
• W2163863124 modified "2023-09-27" @default.
• W2163863124 title "Effects of Methylphenidate on Fatigue and Depression: A Randomized, Double-Blind, Placebo-Controlled Trial" @default.
• W2163863124 cites W1608689417 @default.
• W2163863124 cites W196801323 @default.
• W2163863124 cites W1981482189 @default.
• W2163863124 cites W2035338335 @default.
• W2163863124 cites W2044782312 @default.
• W2163863124 cites W2047297864 @default.
• W2163863124 cites W2047648732 @default.
• W2163863124 cites W2056410714 @default.
• W2163863124 cites W2063931484 @default.
• W2163863124 cites W2067495470 @default.
• W2163863124 cites W2068920752 @default.
• W2163863124 cites W2075030720 @default.
• W2163863124 cites W2076745067 @default.
• W2163863124 cites W2083306135 @default.
• W2163863124 cites W2105028848 @default.
• W2163863124 cites W2112778345 @default.
• W2163863124 cites W2143447257 @default.
• W2163863124 cites W2155475227 @default.
• W2163863124 cites W2156552533 @default.
• W2163863124 cites W2162333871 @default.
• W2163863124 cites W2163352737 @default.
• W2163863124 cites W2937898227 @default.
• W2163863124 doi "https://doi.org/10.1016/j.jpainsymman.2011.03.026" @default.
• W2163863124 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22208450" @default.
• W2163863124 hasPublicationYear "2012" @default.
• W2163863124 type Work @default.
• W2163863124 sameAs 2163863124 @default.
• W2163863124 citedByCount "137" @default.
• W2163863124 countsByYear W21638631242012 @default.
• W2163863124 countsByYear W21638631242013 @default.
• W2163863124 countsByYear W21638631242014 @default.
• W2163863124 countsByYear W21638631242015 @default.
• W2163863124 countsByYear W21638631242016 @default.
• W2163863124 countsByYear W21638631242017 @default.
• W2163863124 countsByYear W21638631242018 @default.
• W2163863124 countsByYear W21638631242019 @default.
• W2163863124 countsByYear W21638631242020 @default.
• W2163863124 countsByYear W21638631242021 @default.
• W2163863124 countsByYear W21638631242022 @default.
• W2163863124 countsByYear W21638631242023 @default.
• W2163863124 crossrefType "journal-article" @default.
• W2163863124 hasAuthorship W2163863124A5012914587 @default.
• W2163863124 hasAuthorship W2163863124A5044204093 @default.
• W2163863124 hasAuthorship W2163863124A5054494090 @default.
• W2163863124 hasAuthorship W2163863124A5061150813 @default.
• W2163863124 hasAuthorship W2163863124A5077121456 @default.
• W2163863124 hasAuthorship W2163863124A5080248259 @default.
• W2163863124 hasAuthorship W2163863124A5086475445 @default.
• W2163863124 hasBestOaLocation W21638631241 @default.
• W2163863124 hasConcept C102959455 @default.
• W2163863124 hasConcept C105795698 @default.
• W2163863124 hasConcept C118552586 @default.
• W2163863124 hasConcept C126322002 @default.
• W2163863124 hasConcept C139719470 @default.
• W2163863124 hasConcept C14184104 @default.
• W2163863124 hasConcept C142724271 @default.
• W2163863124 hasConcept C162324750 @default.
• W2163863124 hasConcept C168563851 @default.
• W2163863124 hasConcept C1862650 @default.
• W2163863124 hasConcept C204787440 @default.
• W2163863124 hasConcept C27081682 @default.
• W2163863124 hasConcept C2776867660 @default.
• W2163863124 hasConcept C2777112843 @default.
• W2163863124 hasConcept C2777353892 @default.
• W2163863124 hasConcept C2779631380 @default.
• W2163863124 hasConcept C2780733359 @default.
• W2163863124 hasConcept C2780783007 @default.
• W2163863124 hasConcept C33923547 @default.
• W2163863124 hasConcept C558461103 @default.
• W2163863124 hasConcept C71924100 @default.
• W2163863124 hasConceptScore W2163863124C102959455 @default.
• W2163863124 hasConceptScore W2163863124C105795698 @default.
• W2163863124 hasConceptScore W2163863124C118552586 @default.
• W2163863124 hasConceptScore W2163863124C126322002 @default.
• W2163863124 hasConceptScore W2163863124C139719470 @default.
• W2163863124 hasConceptScore W2163863124C14184104 @default.
• W2163863124 hasConceptScore W2163863124C142724271 @default.
• W2163863124 hasConceptScore W2163863124C162324750 @default.
• W2163863124 hasConceptScore W2163863124C168563851 @default.
• W2163863124 hasConceptScore W2163863124C1862650 @default.
• W2163863124 hasConceptScore W2163863124C204787440 @default.
• W2163863124 hasConceptScore W2163863124C27081682 @default.
• W2163863124 hasConceptScore W2163863124C2776867660 @default.
• W2163863124 hasConceptScore W2163863124C2777112843 @default.
• W2163863124 hasConceptScore W2163863124C2777353892 @default.
• W2163863124 hasConceptScore W2163863124C2779631380 @default.

• next